3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Next-Generation H+,K+-ATPase Inhibitor for Complex Gastric Acid Research

Introduction

Gastric acid secretion and its dysregulation lie at the heart of numerous gastrointestinal and systemic disorders, ranging from peptic ulcer disease to the gut–liver–brain axis derangements implicated in hepatic encephalopathy. At the molecular level, the H⁺,K⁺-ATPase signaling pathway serves as the final effector in gastric parietal cells, making it a premier target for both mechanistic studies and pharmacological intervention. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845, APExBIO) has emerged as a research-grade, high-purity antiulcer agent for research, setting new standards in the field of gastric acid secretion inhibitor development. This article delivers a comprehensive, integrative analysis of A2845’s scientific utility—expanding beyond previously documented roles to explore novel applications, translational alignment with neuroinflammation models, and advanced integration with systems biology.

Unique Mechanistic Insights: Proton Pump Inhibition and Beyond

Biochemical Properties and Inhibitory Potency

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide distinguishes itself through its potent, selective inhibition of the H⁺,K⁺-ATPase enzyme complex. With an IC₅₀ of 5.8 μM for direct H⁺,K⁺-ATPase inhibition and a remarkable IC₅₀ of 0.16 μM for histamine-induced gastric acid formation, this compound enables precise modeling of the proton pump inhibition pathway. Its chemical profile—C₁₇H₁₉N₃O₃S, molecular weight 345.42, and high purity (98%, HPLC/NMR verified)—ensures reproducible results in both in vitro and in vivo settings. Unlike traditional proton pump inhibitors, its robust antisecretory and antiulcer activity study potential is enhanced by its stability and solubility characteristics (≥17.27 mg/mL in DMSO, insoluble in water/ethanol), allowing for flexible experimental design.

Mechanistic Differentiation from Classical Compounds

While existing articles—such as the analysis at acridine-orange.com—explore the unique mechanism of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide as an H⁺,K⁺-ATPase inhibitor, this review delves deeper into its utility for dissecting the subtleties of the H⁺,K⁺-ATPase signaling pathway, particularly in the context of dynamic feedback loops between acid secretion and mucosal defense. We further differentiate by focusing on the translation of these cellular effects into complex, systems-level models.

Comparative Analysis: Integration with Contemporary Research Workflows

Positioning Among Modern Antiulcer Agents

The landscape of gastric acid secretion research has evolved, with increasing demands for compounds that offer both potency and experimental flexibility. Compared to conventional agents such as omeprazole (often referenced in ic omeprazole literature), A2845 offers a distinct advantage in research reproducibility and selectivity. As detailed in ss-amyloid-1-11.com, the compound’s validation through atomic, verifiable data underscores its utility for antiulcer activity studies and peptic ulcer disease models. This article advances the discussion by systematically mapping how A2845’s chemical and pharmacodynamic properties facilitate integration with high-throughput screening and multi-omics workflows, which are essential for unraveling the complex pathophysiology of gastric acid-related disorders.

Troubleshooting and Workflow Optimization

A critical bottleneck in peptic ulcer disease model research is the reproducibility of antiulcer agent effects across variable biological systems. Referencing the troubleshooting strategies highlighted at bay61-3606.com, we extend the conversation by introducing advanced solutions for compound delivery, stability management (storage at -20°C; avoidance of prolonged solution storage), and solvent compatibility. The high DMSO solubility and solid-state stability of A2845 streamline its application across a spectrum of in vitro/ex vivo and in vivo protocols.

Translational Synergies: Linking Gastric Acid Secretion to Neuroinflammation

Gastric Acid-Related Disorders and the Gut–Liver–Brain Axis

Current research increasingly recognizes the interplay between gastric acid secretion and extra-gastric pathologies, particularly within the context of the gut–liver–brain axis. Recent advances, such as the study by Kong et al. (European Journal of Neuroscience, 2025), highlight the role of gut microbiota and neuroinflammation in chronic hepatic encephalopathy models. While their work focused on Bifidobacterium and fecal microbiota transplantation (FMT) in modulating neuroinflammation, it is important to note that acid secretion modulation via H⁺,K⁺-ATPase inhibition remains an underexplored but potentially pivotal factor in these systemic interactions.

Novel Application: Integrating 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide into Hepatic Encephalopathy Models

Building upon, but distinctly diverging from, prior work such as the exploration at ss-amyloid-1-11.com that touched on neuroinflammation, this article uniquely proposes the integration of A2845 as a tool for dissecting the impact of gastric acid secretion inhibition on the gut–liver–brain axis. Given that acid suppression may alter gut microbiota composition and thus influence systemic inflammation, A2845 could serve as a probe to investigate the mechanistic links between proton pump inhibition, gut microbial shifts, and neuroinflammatory outcomes as measured by noninvasive imaging modalities like [18F]PBR146 PET. By embedding A2845 into multifactorial models of hepatic encephalopathy, researchers can test hypotheses on how gastric acid suppression modulates neuroimmune signaling—potentially revealing new therapeutic targets or biomarkers beyond the purview of microbiota-focused interventions alone (Kong et al., 2025).

Advantages for Systems Biology and Translational Research

Unlike previous reviews that emphasize either molecular mechanism or translational relevance, this article bridges both by advocating for a systems biology approach: leveraging A2845 to simultaneously quantify changes in gastric acid secretion, gut microbiota composition, hepatic inflammation, and neuroinflammatory markers. This holistic integration—made feasible by A2845’s robust pharmacological profile and compatibility with multi-modal assays—marks a substantive evolution in the experimental modeling of gastric acid-related disorders.

Practical Considerations: Handling, Storage, and Experimental Design

Compound Handling and Stability

To ensure optimal activity and reproducibility, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide should be stored at -20°C and protected from prolonged solution storage, as degradation may compromise both purity and efficacy. Its high solubility in DMSO (≥17.27 mg/mL) allows for stock solutions that can be aliquoted and handled with minimal freeze-thaw cycles. The compound’s insolubility in water and ethanol necessitates careful planning for in vitro and in vivo delivery, with DMSO-based vehicles proving most effective for consistency in dosing.

Experimental Workflow Integration

A2845’s validated purity (HPLC and NMR) and consistent batch-to-batch performance make it an ideal candidate for both exploratory and hypothesis-driven research. Whether deployed in acute gastric acid secretion research, long-term antiulcer activity studies, or complex peptic ulcer disease models, the compound’s properties support high-throughput screening, single-cell assays, and in vivo imaging protocols alike. This versatility underpins its growing adoption in leading-edge experimental designs.

Content Differentiation and Hierarchy: Advancing the Field

While atpsolution.com has elucidated actionable protocols and troubleshooting for gastric acid secretion research using A2845, this article positions itself as a cornerstone by offering a comprehensive, systems-level perspective. We synthesize existing mechanistic insights, practical methodologies, and translational applications—culminating in a resource that supports not only robust experimental design but also the conceptual expansion of gastric acid research into neuroinflammatory and hepatological domains.

Conclusion and Future Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) from APExBIO stands at the intersection of chemical precision and translational innovation in the field of H⁺,K⁺-ATPase inhibitors. Its well-characterized potency, stability, and compatibility with advanced research workflows unlock new possibilities in gastric acid-related disorder research, antiulcer activity studies, and the burgeoning exploration of gut–liver–brain crosstalk. Future investigations should leverage A2845 not only for classic peptic ulcer disease models but also as a probe within integrated systems biology platforms, including neuroinflammation imaging and multi-omics profiling. Through such multidisciplinary approaches, researchers can further unravel the complexities of proton pump inhibition pathways and their far-reaching biomedical implications.

For researchers seeking a reliable, versatile, and scientifically validated H⁺,K⁺-ATPase inhibitor, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) represents a next-generation standard for both foundational and translational studies.